Trial Evaluating Efficacy and Safety of Nivolumab (Optivo®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort.

NCT04343144 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

92

Enrollment

OTHER

Sponsor class

Conditions

COVID19- Infection With SARS-CoV-2 Virus

Interventions

DRUG: Nivolumab Injection

Sponsor

Assistance Publique - Hôpitaux de Paris